Investigational Drug Information for Ceralasertib
✉ Email this page to a colleague
What is the development status for investigational drug Ceralasertib?
Ceralasertib is an investigational drug.
There have been 21 clinical trials for Ceralasertib.
The most recent clinical trial was a Phase 1 trial, which was initiated on September 15th 2022.
The most common disease conditions in clinical trials are Neoplasms, Breast Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Parexel.
There are five US patents protecting this investigational drug and forty-two international patents.
Summary for Ceralasertib
| US Patents | 5 |
| International Patents | 42 |
| US Patent Applications | 50 |
| WIPO Patent Applications | 38 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 1 (2022-09-15) |
| Vendors | 48 |
Recent Clinical Trials for Ceralasertib
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Ch | AstraZeneca | Phase 2 |
| Ceralasertib Followed by Durvalumab and Nab-paclitaxel Combination in mTNBC Patients | AstraZeneca | Phase 2 |
| Ceralasertib Followed by Durvalumab and Nab-paclitaxel Combination in mTNBC Patients | IFOM, The FIRC Institute of Molecular Oncology | Phase 2 |
Clinical Trial Summary for Ceralasertib
Top disease conditions for Ceralasertib
Top clinical trial sponsors for Ceralasertib
US Patents for Ceralasertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ceralasertib | ⤷ Sign Up | Chemical compounds | Astrazeneca AB (Sodertalje, SE) | ⤷ Sign Up |
| Ceralasertib | ⤷ Sign Up | Chemical compounds | AstraZeneca AB (Sodertalje, SE) | ⤷ Sign Up |
| Ceralasertib | ⤷ Sign Up | Chemical compounds | AstraZeneca AB (Sodertalje, SE) | ⤷ Sign Up |
| Ceralasertib | ⤷ Sign Up | Chemical compounds | AstraZeneca AB (Sodertalje, SE) | ⤷ Sign Up |
| Ceralasertib | ⤷ Sign Up | Chemical compounds | AstraZeneca AB (Sodertalje, SE) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ceralasertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ceralasertib | Argentina | AR081859 | 2030-06-11 | ⤷ Sign Up |
| Ceralasertib | Australia | AU2011263491 | 2030-06-11 | ⤷ Sign Up |
| Ceralasertib | Brazil | BR112012031561 | 2030-06-11 | ⤷ Sign Up |
| Ceralasertib | Canada | CA2800203 | 2030-06-11 | ⤷ Sign Up |
| Ceralasertib | Chile | CL2012003503 | 2030-06-11 | ⤷ Sign Up |
| Ceralasertib | China | CN103068391 | 2030-06-11 | ⤷ Sign Up |
| Ceralasertib | Colombia | CO6640270 | 2030-06-11 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
